Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly’s stock jumped 3.44% on May 12, ending the day at $759.83, and leaving investors mildly thrilled. This surge placed ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five years, reflecting ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly and Company has earned a consensus rating of “Moderate Buy” from 21 analyst firms, showing solid investor ...